DAPHNE Scale Validation in Frontotemporal Lobar Degeneration
Palabras clave
Abstracto
Descripción
Psycho-behavioral disorders assessment is crucial for the diagnosis and follow-up of patients with frontotemporal degeneration (FTD). DAPHNE scientific staff have therefore developed a quantification and follow-up scale specifically dedicated to patients with FTD in current clinical practice. This scale is called DAPHNE to Disinhibition, Apathy, Perseveration, Hyperorality, Negligence and loss of Empathy. This study aims to validate this scale. This validation will include methodological steps required to develop a new clinical tool, by studying internal consistency, loyalty, and concurrent validity in comparison with validated existing tools. Complementarily, sensitivity and specificity will be assessed via a control population including patients with Alzheimer's disease, , progressive supranuclear palsy and bipolar disorder with cognitive disorders.
fechas
| Verificado por última vez: | 07/31/2017 |
| Primero enviado: | 08/23/2016 |
| Inscripción estimada enviada: | 08/29/2016 |
| Publicado por primera vez: | 09/04/2016 |
| Última actualización enviada: | 08/15/2017 |
| Última actualización publicada: | 08/20/2017 |
| Fecha de inicio real del estudio: | 01/31/2013 |
| Fecha estimada de finalización primaria: | 12/30/2013 |
| Fecha estimada de finalización del estudio: | 12/30/2015 |
Condición o enfermedad
Intervención / tratamiento
Other: Psycho-behavioural assessment
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Fronto-temporal lobar degeneration DAPHNE score building and internal validation through Fronto-temporal lobar degeneration patients. | |
| Control External validation of DAPHNE score among patients with Alzheimer's disease, progressive supranuclear palsy and bipolar disorder with cognitive disorders. |
Criterio de elegibilidad
| Edades elegibles para estudiar | 18 Years A 18 Years |
| Sexos elegibles para estudiar | All |
| Método de muestreo | Non-Probability Sample |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: Group 1: 1. Patients with FTD according Neary (1998) and Raskowsky (2011) diagnostic criteria. 2. Mini-Mental State Examination ≥ 18 3. Consent Group 2 Control: 1. Patients with Alzheimer's disease (MacKahn, 2011), patients with supranuclear palsy (Litvan, 1996) and patients with bipolar disorder with cognitive disorders. criteria. 2. Mini-Mental State Examination ≥ 18 3. Consent Exclusion Criteria: - Minor patient |
Salir
Medidas de resultado primarias
1. Internal validation of DAPHNE Score [Baseline]
